Patrice Cacoub | Medicine and Health Sciences | Excellence in Research Award

Prof. Patrice Cacoub | Medicine and Health Sciences | Excellence in Research Award

Medicine and Health Sciences | Professor | Sorbonne University | France

Prof. Patrice Cacoub is a distinguished clinician‐scientist whose education includes medical training leading to a doctorate and professorial appointment at Sorbonne Université, France, where he holds the chair in internal medicine and leads the Inflammation–Immunopathology–Biotherapy unit; he has also completed additional specialization in immunology, hepatology, and systemic diseases. In his professional experience he serves in leadership roles in hospital and university settings, supervises clinical and translational research groups, and participates actively in international consortia; Prof. Patrice Cacoub has authored 1,011 documents, 53,959 citations, 114 h‐index reflecting prolific output and high influence in his field. His research interests focus on autoimmune diseases, vasculitis, hepatitis C and its extrahepatic manifestations, cryoglobulinaemia, systemic inflammatory disorders, and intersecting fields of immunopathology and therapeutic intervention. He has developed strong research skills in clinical trial design, cohort studies, translational biomarkers, immunological assays, epidemiology, and patient‐oriented outcomes, complemented by skills in multidisciplinary collaboration, grant writing, statistical modelling, and supervising PhD students. His awards and honours include prestigious recognitions by national and international societies in medicine and immunology, election to leadership in professional organizations, invitations to keynote symposia, editorial board memberships, and distinguished lifetime or senior researcher awards, underscoring both scientific merit and impact in patient care. In conclusion Prof. Patrice Cacoub’s combination of rigorous academic training, sustained high‐volume publication record, leadership in clinical and translational research, and demonstrable contributions to improving understanding and treatment of systemic inflammatory and infectious disease places him among the top global experts; his work not only advances knowledge but shapes guidelines, influences public health policy, and serves as a foundation for mentoring and training new generations of researchers.

Profile:  Scopus | ORCID | Google scholar

Selected Publications

  1. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events — 2006 — ~3,652 citations

  2. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease — 1995 — ~3,202 citations

  3. Iron deficiency anaemia — 2016 — ~1,096 citations

  4. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial — 2004 — ~1,039 citations

  5. The DRESS Syndrome: A Literature Review — 2011 — ~1,001 citations

  6. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial — 2007 — ~921 citations

 

Liwu Fu | Pharmacology | Best Researcher Award

Prof. Liwu Fu | Pharmacology | Best Researcher Award

Professor at Sun Yat-sen University Cancer Center, China

Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. 🎓 He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. 🏥 Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. 🔬 With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.

Publication Profile

Scopus

🎓 Educational Background

📌 Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) 🏥. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research 🔬. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine 🧬. His extensive education has shaped his contributions to oncology and anticancer drug development. 🎗️

💼 Professional Experience

🔬 Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) 🏥. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) 🇺🇸. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations 🎗️. He is also an AACR member and has contributed significantly to cancer pharmacology. 🚀

Research Focus

Dr. Liwu Fu’s research focuses on cancer biology 🔬, particularly in tumor immunology 🧬, drug resistance mechanisms 💊, and targeted therapies 🎯. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer 🫁, colorectal cancer 🏥, and leukemia 🧑‍⚕️. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology 🧫 and precision medicine 🏹, making key advancements in overcoming cancer treatment resistance.

Publication Top Notes

📌 Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
🗓 Year: 2025 |  Cited by: 2 |  Molecular Cancer

📌 Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
🗓 Year: 2025 | Advanced Science

📌 Resistance to Antibody–Drug Conjugates: A Review
🗓 Year: 2025 | Acta Pharmaceutica Sinica B

📌 PBA2, a Novel Inhibitor of the β-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
🗓 Year: 2024 | Molecular Cancer

📌 BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
🗓 Year: 2024 |  Cited by: 2 |  Cell Communication and Signaling

Conclusion

Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. 🚀🏆